CA2738549A1 - Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents - Google Patents

Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents Download PDF

Info

Publication number
CA2738549A1
CA2738549A1 CA2738549A CA2738549A CA2738549A1 CA 2738549 A1 CA2738549 A1 CA 2738549A1 CA 2738549 A CA2738549 A CA 2738549A CA 2738549 A CA2738549 A CA 2738549A CA 2738549 A1 CA2738549 A1 CA 2738549A1
Authority
CA
Canada
Prior art keywords
pacap
compound
subject
administered
pacap38
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2738549A
Other languages
English (en)
French (fr)
Inventor
Min Li
Jerome L. Maderdrut
David H. Coy
Vecihi Batuman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of CA2738549A1 publication Critical patent/CA2738549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2738549A 2008-09-25 2009-09-25 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents Abandoned CA2738549A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19416608P 2008-09-25 2008-09-25
US61/194,166 2008-09-25
PCT/US2009/058445 WO2010036936A2 (en) 2008-09-25 2009-09-25 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents

Publications (1)

Publication Number Publication Date
CA2738549A1 true CA2738549A1 (en) 2010-04-01

Family

ID=42060409

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738549A Abandoned CA2738549A1 (en) 2008-09-25 2009-09-25 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents

Country Status (7)

Country Link
US (1) US20110268789A1 (https=)
EP (1) EP2337577A4 (https=)
JP (1) JP2012503674A (https=)
CN (1) CN102215859B (https=)
AU (1) AU2009296456B2 (https=)
CA (1) CA2738549A1 (https=)
WO (1) WO2010036936A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779496A1 (en) 2009-11-02 2011-05-05 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
EP2533795A4 (en) * 2010-02-05 2013-10-16 Univ Tulane USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGUE AS SUPPORTING TREATMENT WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF MTOR COMPLEXES
WO2013074966A1 (en) * 2011-11-17 2013-05-23 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase activating polypeptide (pacap) and pacap analogs for treating contrast -indused nephropathy
CN103145851B (zh) * 2013-02-22 2014-07-02 暨南大学 重组蛋白PACAP38-NtA及其编码基因与应用
EP3565573B1 (en) 2017-01-05 2023-08-23 The Regents of The University of California Pac1 receptor agonists (maxcaps) and uses thereof
ES2677242B1 (es) * 2017-01-31 2019-03-27 Univ Alcala Henares Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer
EP3712164A4 (en) * 2017-11-14 2021-08-18 Senju Pharmaceutical Co., Ltd. PEPTIDE STABILIZED BY PACAP
US20220202905A1 (en) * 2019-05-14 2022-06-30 Senju Pharmaceutical Co., Ltd. Composition for preventing or treating neurotrophic keratitis which contains pacap peptide or stabilized pacap peptide
DE102024001175A1 (de) * 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003228050A1 (en) * 2002-05-03 2003-11-17 Neuronova Ab Therapeutic use of PACAP, Maxadilan, PACAP receptor agonist and/or ADCYAP1R1 in the treatment of CNS disorders
ES2523659T3 (es) * 2004-06-11 2014-11-28 Vectus Biosystems Limited Composiciones y procedimientos para el tratamiento de enfermedades cardiovasculares
WO2006012394A1 (en) * 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
EP2190533A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent

Also Published As

Publication number Publication date
EP2337577A4 (en) 2012-08-15
AU2009296456A1 (en) 2010-04-01
US20110268789A1 (en) 2011-11-03
EP2337577A1 (en) 2011-06-29
WO2010036936A2 (en) 2010-04-01
WO2010036936A9 (en) 2010-07-15
JP2012503674A (ja) 2012-02-09
AU2009296456B2 (en) 2016-06-16
CN102215859B (zh) 2016-04-20
CN102215859A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
AU2009296456B2 (en) Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs as adjunctive treatments with anticancer agents
JP5908406B2 (ja) 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
US20160122406A1 (en) Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
US20120309683A1 (en) USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
US20110251126A1 (en) Intestinal treatment
KR20220145888A (ko) 선택적 gip 수용체 작용제로서의 펩티드
US9006181B2 (en) Treatment of renal dysfunction and multiple myeloma using PACAP compounds
US8580732B2 (en) Peptide therapy for hyperglycemia
US9353171B2 (en) Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140925

FZDE Discontinued

Effective date: 20180216